RedX
Redx Presents Preclinical Data on RXC008, a Potential First-in-Class Therapy to Treat Fibrostenotic Crohn’s Disease, at the UEG Week
Have Any Questions?
Let us help you
Want to keep up to date with our companies?
Subscribe to our newsletter and receive latest information on your favourite companies and JP Jenkins news.